Veradigm Files 2023 and 2024 Annual Reports, Marks Key Milestone in Financial Reporting Recovery
Veradigm, a provider of healthcare technology, clinical solutions, and revenue cycle management services for independent physician practices, has announced the filing of its Annual Reports on Form 10-K for the fiscal years ending December 31, 2023, and December 31, 2024. The filings represent a significant step forward in the company’s efforts to restore compliance with Securities and Exchange Commission (SEC) reporting requirements and strengthen its financial and operational foundation.
The completion of the long-awaited filings is a major milestone for Veradigm as it works to improve transparency, enhance governance, and position itself for future growth. Company leadership emphasized that bringing SEC reporting up to date has been a top priority and remains a critical component of its broader transformation strategy.
Leadership Highlights Progress and Strategic Focus
Donald Trigg, Chief Executive Officer of Veradigm, described the filing as an important achievement in the company’s ongoing efforts to regain momentum and rebuild investor confidence.
According to Trigg, the company has undertaken significant measures to streamline operations, strengthen leadership, and sharpen its strategic focus. He noted that the addition of Christian Greyenbuhl as Chief Financial Officer has strengthened the executive team and enhanced the company’s ability to execute its financial and operational objectives.
Management believes these actions will help the organization reinforce its leadership position among independent healthcare practices while creating a foundation for sustainable and profitable growth. The company has also focused on aligning resources with high-priority initiatives that support long-term value creation.
Encouraging Signs from Early 2026 Performance
Veradigm reported that initial performance indicators from the first quarter of 2026 have been encouraging. Management expects that a more focused product portfolio and platform strategy will contribute positively to revenue growth throughout the year.
The company also anticipates improved profitability resulting from investments in artificial intelligence-driven solutions as well as cost-reduction measures implemented since late 2025. Leadership indicated that these initiatives are designed to increase operational efficiency, enhance customer value, and improve overall financial performance.
By leveraging advanced technology and AI-enabled capabilities, Veradigm aims to deliver stronger solutions to healthcare providers while reducing inefficiencies throughout the healthcare ecosystem.
Review of 2024 Financial Performance
For fiscal year 2024, Veradigm reported revenue of approximately $594 million. This represented a decline from the $626 million recorded in 2023.
Management noted that the prior-year revenue included approximately $19 million in non-recurring settlement-related revenue, making year-over-year comparisons more challenging. Excluding such one-time items, the company’s revenue performance reflected ongoing market and operational factors that affected results during the period.
The company reported a net loss of approximately $292 million for 2024, compared with net income of $49 million in 2023. The significant decline was largely attributed to impairment charges related to goodwill and other assets, as well as transaction-related expenses and additional costs incurred during the year.
While the reported loss weighed on financial results, management emphasized that many of the factors contributing to the decline were non-operational or non-recurring in nature.
Adjusted EBITDA, a commonly used non-GAAP measure of operating performance, totaled approximately $94 million in 2024. This compares with Adjusted EBITDA of $132 million in 2023.
The decrease reflects both lower revenue and the impact of investments and costs associated with the company’s transformation efforts. Nevertheless, management remains focused on improving margins and generating stronger operating performance in future periods.
Preliminary Outlook for 2025
In conjunction with the filing, Veradigm reaffirmed its preliminary financial estimates for fiscal year 2025.
The company expects full-year revenue to fall within a range of approximately $584 million to $589 million. Management believes this outlook reflects current business trends and anticipated performance across its core solutions and services portfolio.
Veradigm also estimates that it will end 2025 with net cash of approximately $45 million. This estimate is based on projected cash and cash equivalents totaling roughly $120 million and debt of approximately $75 million.
The debt balance primarily consists of borrowings under the company’s senior secured term loan facility, which has a maturity date extending to June 18, 2030. Management believes its liquidity position and financial resources provide flexibility to continue executing strategic initiatives while maintaining operational stability.
Focus Shifts to 2025 and 2026 SEC Filings
With the filing of the 2023 and 2024 Form 10-K reports now complete, Veradigm plans to dedicate its full attention to future reporting obligations.
The next major milestone for the company will be the completion and filing of its Form 10-K for the fiscal year ending December 31, 2025. Management has indicated that it is working toward completing that filing before the end of 2026.
Company leaders reiterated their commitment to becoming fully current with SEC filing requirements and maintaining compliance on an ongoing basis. Achieving this objective is viewed as a critical step toward restoring credibility with investors and supporting the company’s long-term strategic goals.
Another important objective is the eventual relisting of Veradigm’s common stock on a national securities exchange. Management believes that maintaining current SEC reporting status will play a key role in advancing those efforts.
Capital Structure and Share Information
As of May 12, 2026, Veradigm reported approximately 109 million shares of common stock outstanding. In addition, the company had approximately 13.3 million unvested restricted stock units outstanding.
These figures provide investors with an updated view of the company’s capital structure as it continues executing its turnaround and growth strategy.
Investor Conference Call Scheduled
To discuss the latest developments and provide additional updates, Veradigm management scheduled an investor conference call and webcast for May 27, 2026.
The event is intended to provide shareholders, analysts, and other stakeholders with an opportunity to hear directly from company leadership regarding recent financial filings, operational progress, strategic priorities, and future expectations.
A replay of the webcast will remain available on the company’s investor relations website for one year, allowing interested parties to access the discussion after the live event.
Supporting Healthcare Through Technology and Data
Veradigm has built its business around helping independent healthcare practices improve both clinical outcomes and financial performance. Through its technology solutions, data platforms, and revenue cycle services, the company supports thousands of healthcare providers across the United States.
The organization serves more than 20,000 provider practices and works to connect healthcare providers, health plans, and biopharmaceutical companies through integrated data and technology solutions.
Increasingly, Veradigm is investing in artificial intelligence and advanced analytics capabilities designed to help eliminate inefficiencies, identify care gaps, improve decision-making, and contribute to a more affordable healthcare system.
Management believes these investments will support future growth opportunities while strengthening the value delivered to customers across the healthcare ecosystem.
The filing of Veradigm’s 2023 and 2024 Form 10-K reports marks an important turning point for the company. While recent financial results reflect challenges, management views the completion of these filings as evidence of meaningful progress in its recovery and transformation efforts.
With a renewed strategic focus, strengthened leadership team, ongoing AI investments, and a commitment to regulatory compliance, Veradigm is positioning itself for the next phase of its development. Company leaders remain focused on improving operational performance, meeting future reporting obligations, and creating long-term value for customers, shareholders, and other stakeholders.
About Veradigm®
Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system.
© 2026 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.
